DexCom — Oct 30, 2025 release

“I am excited to lead Dexcom forward as we finalize 2025 and capitalize on the incredible opportunity ahead of us.” 2025 Annual Guidance Dexcom is raising fiscal year 2025 guidance for Revenue, and updating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin at the following levels: • Revenue of $4.630 - $4.650 billion (approximately 15% growth) • Non-GAAP Gross Profit Margin of approximately 61% • Non-GAAP Operating Margin of approximately 20-21% • Adjusted EBITDA Margin of approximately 29-30% Third Quarter 2025 Financial Results Revenue: In the third quarter of 2025, worldwide revenue grew 22% to $1.209 billion on a reported basis, up from $994.2 million in the third quarter of 2024. Gross Profit: GAAP gross profit totaled $731.4 million or 60.5% of revenue for the third quarter of 2025, compared to $593.8 million or 59.7% of revenue in the third quarter of 2024. Non-GAAP gross profit* totaled $741.3 million or 61.3% of reported revenue for the third quarter of 2025, compared to $625.9 million or 63.0% of reported revenue in the third quarter of 2024. Operating Income: GAAP operating income for the third quarter of 2025 was $242.5 million or 20.1% of revenue, compared to GAAP operating income of $152.0 million or 15.3% of revenue for the third quarter of 2024. 1 Third quarter 2025 organic revenue was $1.198 billion and excludes $11.4 million of foreign exchange impact. Non-GAAP operating income* for the third quarter of 2025 was $272.9 million or 22.6% of reported revenue, compared to non-GAA